agilon health Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at agilon health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.3214 $ to 129.80 $ · Last price: 89.20 $ (As of: September 18, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Medical Care Facilities
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| agilon health Inc AGL | 1.5 | – | -104.5 | 0.2 | 0.7 | -2.1 | 212.9 |
| HCA Healthcare, Inc. HCA | 94.9 | 15.2 | 9.0 | 42.6 | 15.0 | 7.1 | 7.4 |
| Tenet Healthcare Corporation THC | 22.6 | 14.0 | 5.8 | 41.7 | 17.9 | 3.1 | 42.8 |
| Encompass Health Corp EHC | 12.1 | 21.1 | 9.8 | 43.9 | 19.0 | 10.5 | -0.2 |
| DaVita HealthCare Partners Inc DVA | 11.7 | 18.2 | 8.9 | 32.4 | 13.9 | 6.5 | 43.0 |
| Universal Health Services Inc UHS | 10.7 | 7.7 | 5.5 | 44.6 | 11.2 | 9.7 | -3.1 |
| The Ensign Group Inc ENSG | 10.2 | 29.1 | 19.3 | 16.6 | 9.0 | 18.7 | 5.6 |
| Chemed Corp CHE | 6.7 | 29.7 | 15.7 | 33.1 | 12.9 | 4.1 | 11.2 |
| PACS Group, Inc. PACS | 6.5 | – | 20.3 | 17.3 | 8.5 | 29.3 | 274.9 |
| Median of companies shown | 10.7 | 18.2 | 9.0 | 33.1 | 12.9 | 7.1 | 11.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 794 | -107 | -283 | -18.40 | -104 | -232 | 403 |
| 2020 | 1,218 | -57 | -60 | -3.90 | -53 | -285 | 446 |
| 2021 | 1,521 | -372 | -406 | -27.25 | -148 | 1,092 | 1,586 |
| 2022 | 2,388 | -105 | -107 | -6.53 | -131 | 1,041 | 1,697 |
| 2023 | 4,316 | -232 | -263 | -16.05 | -156 | 662 | 1,741 |
| 2024 | 6,061 | -292 | -260 | -15.83 | -58 | 471 | 1,734 |
| 2025 | 5,933 | -421 | -405 | -24.48 | -106 | 127 | 1,271 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -6.42 | – | 1,523 | 86.70 | -6.90 | 16 | 4 |
| 2025: Q1 | 0.73 | – | 1,533 | -4.50 | 0.80 | -32 | -43 |
| 2025: Q2 | -6.31 | – | 1,395 | -5.90 | -7.50 | -35 | -38 |
| 2025: Q3 | -6.65 | – | 1,435 | -1.10 | -7.70 | -18 | -21 |
| 2025: Q4 | -11.39 | – | 1,570 | 3.10 | -12.00 | -21 | -38 |
| 2026: Q1 | 1.80 | 145.30 | 1,421 | -7.30 | 2.10 | 24 | 21 |
| 2026: Q2 | 1.04 | 116.50 | 1,495 | 7.10 | 1.20 | -57 | -61 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.65 | -5.34 – 2.07 | 5,826 | 104.0% | 12 |
| 12/31/2027 | 2.66 | -0.55 – 6.15 | 6,254 | 206.0% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 35.4%
- More than 10% revenue growth is expected for the coming year 6.3%
- Share count grows by less than 3% a year 0.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -4.1%
- Gross margin at 40% or higher and without meaningful erosion -3.2%
- Goodwill from acquisitions does not grow faster than revenue 3.3%
- Net debt below twice EBITDA 248 m net cash
- Operating cash flow covers the profits of the last three years 608 m
- Return on capital at 15% or higher, or up versus two years ago -216.2%
- Insiders hold at least 10% or are net buyers 3.2%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 39.8%
- Exp. sales growth 3Y > 5% 2.7%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 2.7%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -2,082.0%
- ROCE > 15% -216.2%
- Expected return > 10% -5.4%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 16, 2026 | Gertsch Timothy | Chief Accounting Officer | Other | 17 | 96.90 | 1,647 |
| Aug 1, 2026 | Zamore Denise | Chief Legal Officer | Other | 37 | 91.61 | 3,390 |
The company
About the Company
agilon health, inc. bietet Gesundheitsdienstleistungen für Senioren über Hausärzte in den Gemeinden der USA an.
- Employees
- 856
- Headquarters
- Westerville, OH
- Address
- 440 Polaris Parkway, 43082 Westerville, United States
- Phone
- 562 256 3800
- Website
- agilonhealth.com
- IPO Date
- 04/15/2021
- ISIN
- US00857U2069
- Stock Split
- 1:25 on 03/31/2026
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey Alan Schwaneke CPA | Executive VP & CFO | 1976 |
| Denise Zamore | Chief Legal Officer & Secretary | 1975 |
| Girish Venkatachaliah | Advisor | 1974 |
| Benjamin Shaker | Chief Markets Officer | 1983 |
| Timothy Patrick O'Rourke | CEO & Director | – |
| Timothy Gertsch | Chief Accounting Officer | 1987 |
| Varun Anand | Interim Chief Technology Officer | – |
| Evan Smith C.F.A. | Senior Vice President of Investor Relations | – |
| Bill Farry | Chief of Technology Innovation | – |
| Kenny Bellendir | Markets Chief Financial Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/05/2026 agilon health, inc. (AGL): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/21/2026 agilon health, inc. (AGL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits SEC ↗
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.